Which amylin receptor agonists are in development as of October 2026?
Three amylin receptor agonists lead clinical development in October 2026: cagrilintide from Novo Nordisk, mostly studied inside the CagriSema combination; petrelintide from Zealand Pharma and Roche; and eloralintide from Eli Lilly, studied alone and with tirzepatide as EloraTZP. All three reported data between 2026-09-21 and 2026-09-30.
This overview reports trial registrations and company statements as facts, with the source for each. It does not report outcome magnitudes or describe any use. Metatide lists cagrilintide for laboratory research, and the GLP-1 vs cagrilintide comparison covers how the amylin and GLP-1 receptor systems differ at the bench.
What is amylin and which receptors does it act on?
Amylin is a 37-residue peptide hormone co-secreted with insulin by pancreatic beta cells. Native human amylin aggregates readily, which makes it a poor research tool on its own and is the main reason long-acting, non-aggregating analogs were engineered. Its receptors are not a single protein but a pairing.
An amylin receptor is the calcitonin receptor (CTR), a class B G-protein-coupled receptor, combined with one of three receptor activity-modifying proteins, RAMP1, RAMP2 or RAMP3. The three pairings are designated AMY1, AMY2 and AMY3. Without a RAMP, the calcitonin receptor responds preferentially to calcitonin; with a RAMP, it gains high affinity for amylin. This is why amylin analogs are often described by how they act at the calcitonin receptor as well as at the amylin receptors, and why "selective amylin receptor agonist" and "dual amylin and calcitonin receptor agonist" are meaningful distinctions. The amylin system is separate from the GLP-1 and GIP receptors covered in the incretin compound landscape.
How do cagrilintide, petrelintide and eloralintide compare?
The three candidates differ by sponsor, by how each developer describes the receptor profile, and by how far each has moved. The table uses ClinicalTrials.gov records and company or press statements as retrieved on 2026-10-19. Receptor descriptions are the sponsors' or publishers' wording.
| Compound |
Sponsor |
Receptor profile (as described) |
Stage, Oct 2026 |
Latest readout |
Source |
| Cagrilintide (in CagriSema) |
Novo Nordisk |
Long-acting amylin receptor agonist, combined with semaglutide |
NDA filed Dec 2025; FDA decision expected Q4 2026 |
REIMAGINE 5 topline, 2026-09-21 |
Novo Nordisk release; NCT06534411 |
| Petrelintide |
Zealand Pharma with Roche |
Long-acting amylin analog |
Phase 3 (ZUPREME-3, -4, -5 registered 2026-09-28) |
Phase 2 paper in The Lancet Diabetes & Endocrinology, 2026-09-29 |
NCT06662539; NCT07843498 |
| Eloralintide (LY3841136) |
Eli Lilly |
Once-weekly selective amylin receptor agonist |
Phase 3 alone (ENLIGHTEN); EloraTZP phase 3 (AMPLIFY) posted 2026-10-19 |
EloraTZP phase 2b at EASD, 2026-09-30 |
NCT06603571; NCT07321886 |
Cagrilintide is the only one of the three with a regulatory filing. Petrelintide and eloralintide are each in phase 3 programs that were registered within the past year.
What is cagrilintide and where does CagriSema stand?
Cagrilintide is Novo Nordisk's long-acting amylin analog. Metatide's catalog data lists it as C₁₉₄H₃₁₂N₅₄O₅₉S₂, 4409.01 g/mol, CAS 1415456-99-3, and PubChem indexes the same formula under CID 171397054. In the clinic it is mainly studied as CagriSema, a fixed combination with semaglutide, the GLP-1 receptor agonist sold for research as GLP-1(S).
On 2026-09-21 Novo Nordisk released topline results for two phase 3 trials. REIMAGINE 5 (NCT06534411) enrolled adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both, and compared once-weekly CagriSema with tirzepatide; per the release, "the dual primary endpoints were change in HbA1c and relative change in body weight from baseline to week 60." ClinicalTrials.gov lists 1,023 participants and a completed status. REDEFINE 9 compared CagriSema with placebo, and Novo reported its primary superiority endpoint as met.
On regulation, the same release states that Novo filed a New Drug Application with the FDA in December 2025 and expects a decision in Q4 2026, and that CagriSema "remains investigational." A TIME report on 2026-10-01 likewise described an FDA decision as expected by the end of the year.
What is petrelintide and what was published in September 2026?
Petrelintide is a long-acting amylin analog developed by Zealand Pharma, now co-developed with Roche. Its phase 2 results were published in The Lancet Diabetes & Endocrinology and presented at EASD 2026 in Milan, with online publication on 2026-09-29. The program moved into phase 3 the day before.
ClinicalTrials.gov lists ZUPREME (NCT06662539), a completed Zealand-sponsored phase 2 trial of once-weekly petrelintide versus placebo with 493 participants and a registered primary endpoint of percent change from baseline in body weight to week 28. A second completed phase 2 trial (NCT06926842, 221 participants) studied participants with type 2 diabetes. On 2026-09-28 Roche posted three phase 3 registrations: ZUPREME-3 (NCT07843498, 3,900 estimated), ZUPREME-4 (NCT07843485, 600) and ZUPREME-5 (NCT07843472, 2,500), all recruiting. Roche has also registered ZYNERGY (NCT07589686), a phase 2 study pairing petrelintide with enicepatide (RO7795068).
Commentary on the EASD presentation, including ConscienHealth's 2026-09-30 write-up, focused on tolerability, reporting that discontinuations for adverse events were close to placebo.
What is eloralintide and what did Lilly present at EASD 2026?
Eloralintide (LY3841136) is Eli Lilly's amylin candidate, described by Lilly as a once-weekly selective amylin receptor agonist. At EASD 2026 on 2026-09-30, Lilly presented phase 2b data for EloraTZP, eloralintide given alongside tirzepatide, the dual GIP and GLP-1 receptor agonist sold for research as GLP-2(T).
The trial (NCT06603571) was a 48-week, double-blind, placebo-controlled phase 2b study that randomized 367 adults with obesity or overweight and type 2 diabetes in the United States and Argentina, per Lilly's 2026-09-30 announcement as reported by HCPLive. Its registered primary endpoint is percent change from baseline in body weight. An earlier phase 2 trial of eloralintide alone (NCT06230523, 263 participants) is listed as completed.
Eloralintide alone is in phase 3 under the ENLIGHTEN name, including ENLIGHTEN-1 (NCT07321886, 1,980 participants), ENLIGHTEN-2, -3, -4 and -6, all listed as recruiting. Lilly stated it plans phase 3 trials of a co-formulated EloraTZP by the end of 2026, and two of them, AMPLIFY-1 (NCT07881432) and AMPLIFY-2 (NCT07881458), were first posted on ClinicalTrials.gov on 2026-10-19 as not yet recruiting.
Why are amylin agonists paired with incretin agonists?
Each combination reviewed here pairs an amylin agonist with an incretin agonist: cagrilintide with semaglutide, eloralintide with tirzepatide, petrelintide with enicepatide. The logic is receptor coverage. Amylin receptors and incretin receptors are distinct class B GPCR systems, so a combination engages two signaling systems that a single molecule does not.
Both systems are expressed in hindbrain and hypothalamic regions studied in nutrient-response signaling, but they use different receptors and different accessory proteins. For receptor pharmacology research, that independence is the point: the systems can be probed separately with a selective agonist and together with a combination, and the RAMP dependence of amylin receptors adds a variable that incretin receptors do not have.
What do these readouts mean for laboratory research?
For bench research, the 2026 readouts mainly change which comparators matter. Cagrilintide is the best-characterized reference amylin analog, eloralintide adds a compound described as selective for amylin receptors, and petrelintide adds a third long-acting analog with its own published phase 2 dataset.
None of the clinical results changes the status of research-grade material. Research use still depends on identity by mass spectrometry, matching the 4409.01 g/mol figure for cagrilintide, and purity by HPLC. Registry records and company releases establish what sponsors have studied and plan to study; they do not describe research-grade compounds, and nothing in this overview should be read as describing any use outside the laboratory.
All compounds referenced in this article are supplied for research purposes only and are not for human use. Nothing here describes or endorses any use outside laboratory research. These products are not intended to diagnose, treat, cure, or prevent any disease.
